CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy

References

• Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944–8. doi:10.1111/febs.14466.
   PubMed Web of Science ®Google Scholar
• Bennett LD, Fox JM, Signoret N. Mechanisms regulating chemokine receptor activity. Immunology. 2011;134(3):246–256. doi:10.1111/j.1365-2567.2011.03485.x.
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines in pathology and medicine. J Intern Med. 2001;250(2):91–104. doi:10.1046/j.1365-2796.2001.00867.x.
   PubMed Web of Science ®Google Scholar
• Proudfoot AEI. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol. 2002;2(2):106–115. doi:10.1038/nri722.
   PubMed Web of Science ®Google Scholar
• Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol Life Sci. 2019;76(24):4869–4886. doi:10.1007/s00018-019-03255-6.
   PubMed Web of Science ®Google Scholar
• Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29(1):10–21. doi:10.1038/s41417-021-00303-x.
   PubMed Web of Science ®Google Scholar
• Kothandan G, Gadhe CG, Cho SJ, Verma C. Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study. PloS One. 2012;7(3):e32864. doi:10.1371/journal.pone.0032864.
   PubMed Web of Science ®Google Scholar
• de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O’Brien B, Weathers S-P, Loghin M, Kamiya Matsouka C, Yung WKA, et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020;22(4):539–549. doi:10.1093/neuonc/noz185.
   PubMed Web of Science ®Google Scholar
• Dunay IR, Damatta RA, Fux B. Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity. 2008;29(2):306–317. doi:10.1016/j.immuni.2008.05.019.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, et al. Monocytic CCR2+ myeloid derived suppressor cells promote immune escape by limiting activated CD8 T cell infiltration into the tumor microenvironment. Cancer Res. 2012;72(4):876–886. doi:10.1158/0008-5472.CAN-11-1792.
   PubMed Web of Science ®Google Scholar
• Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007;9(7):556–562. doi:10.1593/neo.07307.
   PubMed Web of Science ®Google Scholar
• Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, Yuan Z-R, Roberts A, Zhang L, Zheng B, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell. 2012;11(6):812–824. doi:10.1016/j.stem.2012.08.013.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang Q, Xu M, Wang L, Chen X, Feng Y, Li Y, Zhang X, Cui W, Jia X, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41. doi:10.1186/s12943-020-01165-x.
   PubMed Web of Science ®Google Scholar
• Heiskala M, Leidenius M, Joensuu K, Heikkilä P. High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer. Virchows Arch. 2019;474(1):3–12. doi:10.1007/s00428-018-2461-7.
   PubMed Web of Science ®Google Scholar
• Boi SK, Orlandella RM, Gibson JT, Turbitt WJ, Wald G, Thomas L, Buchta Rosean C, Norris KE, Bing M, Bertrand L, et al. Obesity diminishes response to PD-1-based immunotherapies in renal cancer. J Immunother Cancer. 2020;8(2):e000725. doi:10.1136/jitc-2020-000725.
   PubMed Web of Science ®Google Scholar
• Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T Cells and myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5671–5682. doi:10.1158/0008-5472.CAN-16-0144.
   PubMed Web of Science ®Google Scholar
• Ohta M, Kitadai Y, Tanaka S. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol. 2003;22:773–778. doi:10.3892/ijo.22.4.773.
   PubMed Web of Science ®Google Scholar
• Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze TJ, Razon H, Hawila E, Wildbaum G, et al. CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions. Cancer Res. 2018;78(1):157–167. doi:10.1158/0008-5472.CAN-17-0348.
   PubMed Web of Science ®Google Scholar
• Yang L, Wang B, Qin J, Zhou H, Majumdar APN, Peng F. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. Immunopharmacol Immunotoxicol. 2018;40(1):91–97. doi:10.1080/08923973.2017.1417997.
   PubMed Web of Science ®Google Scholar
• Walens A, DiMarco AV, Lupo R, Kroger BR, Damrauer JS, Alvarez JV. CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. Elife. 2019;8:e43653. doi:10.7554/eLife.43653.
   PubMed Web of Science ®Google Scholar
• Sima AR, Sima HR, Rafatpanah H, Hosseinnezhad H, Ghaffarzadehgan K, Valizadeh N, Mehrabi Bahar M, Hakimi HR, Masoom A, Noorbakhsh A, et al. Serum chemokine ligand 5 (CCL5/RANTES) level might be utilized as a predictive marker of tumor behavior and disease prognosis in patients with gastric adenocarcinoma. J Gastrointest Cancer. 2014;45(4):476–480. doi:10.1007/s12029-014-9652-5.
   PubMedGoogle Scholar
• Flores-Toro JA, Luo D, Gopinath A, Sarkisian MR, Campbell JJ, Charo IF, Singh R, Schall TJ, Datta M, Jain RK. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proceedings of the National Academy of Sciences 2020; 117:1129–1138.
   Google Scholar
• Laudati E, Currò D, Navarra P, Lisi L. Blockade of CCR5 receptor prevents M2 microglia phenotype in a microglia-glioma paradigm. Neurochem Int. 2017;108:100–108. doi:10.1016/j.neuint.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Wang J, Saung MT, Li K, Fu J, Fujiwara K, Niu N, Muth S, Wang J, Xu Y, Rozich N, et al. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. J Exp Med. 2022;219(5):e20211631. doi:10.1084/jem.20211631.
   PubMed Web of Science ®Google Scholar
• Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7:e1466769. doi:10.1080/2162402X.2018.1466769.
   PubMed Web of Science ®Google Scholar
• Carter PH, Brown GD, Cherney RJ, Batt DG, Chen J, Clark CM, Cvijic ME, Duncia JV, Ko SS, Mandlekar S, et al. Discovery of a potent and orally bioavailable dual antagonist of CC chemokine receptors 2 and 5. ACS Med Chem Lett. 2015;6(4):439–444. doi:10.1021/ml500505q.
   PubMed Web of Science ®Google Scholar
• Puengel T, Lefere S, Hundertmark J, Kohlhepp M, Penners C, Van de Velde F, Lapauw B, Hoorens A, Devisscher L, Geerts A, et al. Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis. Int J Mol Sci. 2022;23(12):6696. doi:10.3390/ijms23126696.
   PubMed Web of Science ®Google Scholar
• Jackson C, Cherry C, Bom S, Dykema AG, Thompson E, Zheng M, Ji Z, Hou W, Li R, Zhang H, et al. Distinct Myeloid Derived Suppressor Cell Populations Promote Tumor Aggression in Glioblastoma. bioRxiv. 2023:2023.03.26.534192.
   Google Scholar
• Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411–420. doi:10.1038/nbt.4096.
   PubMed Web of Science ®Google Scholar
• Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath MJ, Prlic M, et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 2015;16(1):278. doi:10.1186/s13059-015-0844-5.
   PubMedGoogle Scholar
• Sergushichev AA. GAM: a web-service for integrated transcriptional and metabolic network analysis. Nucleic Acids Res. 2016;44(W1):W194–200. doi:10.1093/nar/gkw266.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang K-N, Wang Q, Li G, Zeng F, Zhang Y, Wu F, Chai R, Wang Z, Zhang C, et al. Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genomics, Proteomics & Bioinformatics. 2021;19(1):1–12. doi:10.1016/j.gpb.2020.10.005.
   PubMed Web of Science ®Google Scholar
• Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–449. doi:10.1016/j.immuni.2015.09.001.
   PubMed Web of Science ®Google Scholar
• Felsenstein M, Blank A, Bungert AD, Mueller A, Ghori A, Kremenetskaia I, Rung O, Broggini T, Turkowski K, Scherschinski L, et al. CCR2 of tumor microenvironmental cells is a relevant modulator of glioma biology. Cancers Basel. 2020;12(7):1882. doi:10.3390/cancers12071882.
   PubMed Web of Science ®Google Scholar
• Tan MCB, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC. Disruption of CCR5-dependent homing of regulatory T Cells Inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009;182(3):1746–1755. doi:10.4049/jimmunol.182.3.1746.
   PubMed Web of Science ®Google Scholar
• Strauss L, Mahmoud MAA, Weaver JD, Tijaro-Ovalle NM, Christofides A, Wang Q, Pal R, Yuan M, Asara J, Patsoukis N, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020;5(43):eaay1863. doi:10.1126/sciimmunol.aay1863.
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38):eabd2712. doi:10.1126/sciadv.abd2712.
   PubMed Web of Science ®Google Scholar